Posts tagged orphan drugs.
Blogs
8 minute read
On Wednesday, October 14, 2015, the U.S. District Court for the District of Columbia (the "Court"), Judge Rudolph Contreras, vacated the Health Resources and Services Administration's ("HRSA") interpretive rule on Orphan Drugs ("the Interpretative Rule") as "arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law."[1] As a result of the ruling, pharmaceutical manufacturers are not required to provide 340B discounts to certain types of covered entities for Orphan Drugs, even when the drugs are prescribed for uses other than to treat the rare ...
Blog Editors
Recent Updates
- Closer Look at H.R. 7291: What the “GRAS Oversight and Transparency Act” Could Mean for Dietary Supplements
- Diagnostic Imaging Interoperability Request for Information Shines a Spotlight on the Lack of Patient-Centered Longitudinal Health Records
- DOJ Deputy Assistant Attorney General Addresses FCA Enforcement Priorities and Reinforces Commitment to Robust Enforcement
- Interested in Opening a Medical Spa? (Part III): Here’s (More) That You Need to Know
- IRS Issues Guidance Regarding Group Exemption Letters